Mar 24, 2020
Biosimilars Market Worth $35.7 Billion by 2025 - Exclusive Report by MarketsandMarkets(TM)
Jan 30, 2020
Protalix BioTherapeutics to Participate in the 16th Annual WORLDSymposium(TM) 2020
Jan 22, 2020
Ascletis Received Approval of Clinical Trials in HBV Patients for ASC22, a Subcutaneously Administered PD-L1 Antibody
Mar 11, 2019
Arthritis & Rheumatology Publishes the First Randomized Placebo-Controlled Study Over 52 Weeks in Non-Radiographic Axial Spondyloarthritis Showing Positive Results for CIMZIA® (certolizumab pegol)
Dec 05, 2018
PharmaEssentia Updates Progress of Ropeginterferon Alfa-2b Clinical Program
Nov 20, 2018
Ascletis and Roche enter exclusive Pegasys partnership in China for viral Hepatitis
Oct 29, 2018
MYR Pharma Announces Presentation of Interim Results of MYR 203, a Phase 2 Study of Myrcludex in Combination with Pegylated Interferon in Chronic Hepatitis Delta
Oct 17, 2018
Eiger BioPharmaceuticals Announces Positive Phase 2 LIMT Study End of Treatment Data with Pegylated Interferon Lambda Monotherapy in Hepatitis Delta Virus (HDV) Infection
Aug 15, 2018
PEGylated Drugs Market in Europe and North America will achieve 5% CAGR to bypass $10.5 Billion by 2024
Aug 13, 2018
PEGylated Protein Therapeutics Market Worth $17,813 Million by 2025 | CAGR: 6.9% - Allied Market Research
May 29, 2018
UCB Announces the Approval of CIMZIA® (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
May 16, 2018
CIMZIA® (certolizumab pegol) is the First Therapy to Demonstrate Positive Results in a 52-week, Placebo Controlled Non-Radiographic Axial Spondyloarthritis Study
Apr 12, 2018
Innovations Shines a Light on Advances in Biopharma Manufacturing and Clinical Trial Processes
Mar 22, 2018
CIMZIA® (certolizumab pegol) label update marks major advance for women of childbearing age with chronic inflammatory disease in the U.S.
Feb 22, 2018
MYR Pharma Announces Completion of Active Treatment Phase in MYR 203 Clinical Trial of Myrcludex B
Nov 08, 2017
Prolong Pharmaceuticals to Present New Research on SANGUINATE®, an Investigational Treatment Under Evaluation for Vaso-Occlusive Crisis (VOC) in Patients with Sickle Cell Disease, at ASH Annual Meeting
Jul 27, 2017
Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection
Jul 26, 2017
Jazz Pharmaceuticals and XL-protein GmbH Enter Into a License Agreement on PASylation® Technology to Develop Long-Acting Asparaginase Product Candidates
Jun 25, 2017
AOP Orphan and PharmaEssentia announce latest clinical results for Ropeginterferon alfa-2b in Polycythemia Vera from 3 abstracts presented at the 22nd Congress of the European Hematology Association (EHA) in Madrid
Jun 05, 2017
IBBR faculty win two Maryland Innovation Initiative (MII) grants